BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2001

View Archived Issues

Licensing opportunity from NIH: virus-like particles as unlinked adjuvants

Read More

Karo Bio updates collaborative and internal development projects

Read More

Micrologix suspends MBI-853NL development program; focus shifts to later stage products

Read More

Enrollment complete in second pivotal phase III trial of Cidecin

Read More

RANTES analogue stimulates HIV replication at high concentrations via the MAPK/ERK pathway

Read More

Overall superior safety profile of BMS-232632 vs. older protease inhibitors confirmed

Read More

Resistance profile of BCH-10618 suggests further development warranted

Read More

Long-term results reported from Thai study of Remune monotherapy

Read More

Small-molecule CCR5 antagonists as a promising new class of antiretrovirals

Read More

Autoimmune and inflammatory disease therapy alliance between Icos and Biogen

Read More

Genome Therapeutics and Wyeth-Ayerst extend osteoporosis genomics alliance

Read More

Agreement signed for codevelopment of tissue-remodeling COPD treatment

Read More

Controlled trial shows no additional benefit for montelukast in difficult-to-treat asthma patients

Read More

Transdermal dopamine agonist reduces levodopa use in PD

Read More

Immunex seeks FDA approval of Enbrel for psoriatic arthritis

Read More

Thyroid disease therapy now available in Japan

Read More

GeneTrove division of Isis teams up with Celera Genomics for antisense gene functionalization

Read More

Antiinflammatory and cardioprotective effects of simvastatin in ApoE-deficient mice

Read More

EluSys raises funds to support Heteropolymer development program

Read More

Neurochem provides update on Fibrillex development

Read More

Vion's Triapine enters second phase I combination trial

Read More

Aventis gains license to Asta Medica's dexlipotam

Read More

Selective ERbeta receptor agonists claimed for use in osteoporosis

Read More

Naturally produced compound WK-6326 inhibits IL-4 activity and bacterial growth

Read More

New compounds from Alcon particularly useful for treatment of dry eye

Read More

Melatonin receptor ligands exert potent effects on circadian rhythms

Read More

Neuroprotective aminoalcohol derivatives designed by Seikagaku

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing